What is claimed is:

1. A topical skin preparation comprising glucosamine in an emollient base.

2. The preparation of claim 1, further comprising a keratolytic.

3. The preparation of claim 2, wherein the keratolytic comprises coal tar extract.

4. The preparation of claim 2, wherein the keratolytic comprises a salicylate.

5. The preparation of claim 4, wherein the salicylate comprises salicylic acid.

6. The preparation of claim 1, further comprising at least one antioxidant anti-inflammatory.

7. The preparation of claim 6, wherein the at least one antioxidant anti-inflammatory is from an herbal source.

8. The preparation of claim 6, wherein the at least one antioxidant anti-inflammatory comprises berberine.

9. The preparation of claim 6, wherein the at least one antioxidant anti-inflammatory comprises oleuropein.

10. The preparation of claim 6, wherein the at least one antioxidant anti-inflammatory comprises berberine and oleuropein.

11. The preparation of claim 6, wherein the at least one antioxidant anti-inflammatory comprises approximately in the range of 1.5-17.5% of the preparation by weight.

12. The preparation of claim 1, wherein the emollient base comprises moisturizing cream.

13. The preparation of claim 1, whereby the preparation provides symptomatic relief of psoriasis.

14. The preparation of claim 1, wherein glucosamine comprises approximately in the range of 5-25% of the preparation by weight.

15. The preparation of claim 10, wherein the relative amounts of glucosamine, berberine and oleuropein comprise a ratio of approximately 9:1.75:1 of glucosamine, berberine and oleuropein, respectively.

16. The preparation of claim 10, wherein glucosamine comprises approximately in the range of 5-25% by weight, berberine comprises approximately in the range of 1-10% by weight and oleuropein comprises approximately in the range of 0.5-7.5% by weight of the preparation.

17. The preparation of claim 16, wherein the emollient base comprises the balance of the preparation by weight.

18. A formulation comprising glucosamine in an emollient base, wherein the formulation may be suitable for topical application on human skin, and further wherein the formulation at least partially suppresses, local to the area of topical application, the production of at least one cytokine that stimulates the proliferation of apoptosis-resistant keratinocytes.

19. The formulation of claim 18, wherein the at least one cytokine comprises interleukin-2.

20. The formulation of claim 18, wherein the at least one cytokine comprises interferon gamma.

21. The formulation of claim 18, wherein the at least one cytokine comprises interleukin-2 and interferon-gamma.

22. The formulation of claim 18, wherein the at least one cytokine is suppressed due to at least suppression of a T-cell population that secretes the at least one cytokine.

23. The formulation of claim 22, wherein the T-cell population comprises $CD8^+$ T-cells.

24. The formulation of claim 18, wherein the formulation suppresses CD8+ T-cells.

25. The formulation of claim 18, further comprising at least one antioxidant anti-inflammatory.

26. The formulation of claim 25, wherein the at least one antioxidant anti-inflammatory is from an herbal source.

27. The formulation of claim 26, wherein the at least one antioxidant anti-inflammatory comprises berberine.

28. The formulation of claim 26, wherein the at least one antioxidant anti-inflammatory comprises oleuropein.

29. The formulation of claim 25, further comprising coal tar extract.

30. The formulation of claim 18, wherein the emollient base comprises moisturizing cream.

31. The formulation of claim 18, whereby the formulation provides symptomatic relief of psoriasis.

32. The formulation of claim 25, wherein the at least one antioxidant anti-inflammatory comprises berberine and oleuropein.

33. The formulation of claim 32, wherein glucosamine, berberine and oleuropein are present in relative amounts comprising a ratio of approximately 9: 1.75: 1 of glucosamine, berberine and oleuropein, respectively.

34. The formulation of claim 32, wherein glucosamine comprises approximately in the range of 5-25% by weight, berberine comprises approximately in the range of 1-10% by weight and oleuropein comprises approximately in the range of 0.5-7.52% by weight of the formulation.

35. The formulation of claim 34, wherein the emollient base comprises the balance of the formulation by weight.

36. The formulation of claim 18, wherein glucosamine comprises approximately 5-25% of the formulation by weight.

37. The formulation of claim 18, wherein the skin further comprises blood vessels capable of undergoing angiogenesis and the skin also further comprises connective tissue, whereby the formulation inhibits angiogenesis without substantially compromising the connective tissue around the area of application.

38. The formulation of claim 18, wherein the skin further comprises connective tissue, whereby the formulation bestows anti-inflammatory benefits to the skin around the area of application without substantially compromising connective tissue around the area of application.

39. The formulation of claim 18, wherein the formulation stimulates the production of mucopolysaccharides in the skin around the area of application.

40. A formulation suitable for topical application on mammalian skin, the formulation comprising glucosamine and extract from at least one herb, wherein the at least one herb extract elicits at least one of the following biological effects: anti-inflammatory, antioxidant, antibacterial, antimicrobial, anti-pruritic, anti-platelet adhesion, vasodilation or keratolysis.

41. The formulation of claim 40, wherein the at least one herb extract comprises olive leaf extract.

42. The formulation of claim 40, wherein the at least one herb extract comprises Oregon grapeseed extract.

43. The formulation of claim 40, wherein the at least one extract comprises olive leaf extract and Oregon grapeseed extract.

44. The formulation of claim 40, whereby the glucosamine and the at least one extract act synergistically on the skin to mitigate skin ailments.

45. The formulation of claim 41, wherein the olive leaf extract comprises oleuropein.

46. The formulation of claim 42, wherein the Oregon grapeseed extract comprises berberine.

47. The formulation of claim 40, wherein the at least one extract comprises oleuropein and berberine.

48. A formulation suitable for topical application on mammalian skin, the formulation comprising:

approximately in the range of 5 - 25% glucosamine by weight;

approximately in the range of 1 - 10% berberine by weight;

approximately in the range of 0.5 - 7.5% oleuropein by weight; and

approximately in the range of 47.5 - 93.5% emollient by weight,

whereby the formulation mitigates skin ailments local to the area of application.

49. The formulation of claim 48, wherein the skin ailment comprises psoriasis.

50. The formulation of claim 48, wherein the skin ailment comprises dermatitis.

51. The formulation of claim 48, wherein the skin ailment comprises hyperproliferation of apoptosis-resistant keratinocytes.

52. The formulation of claim 48, wherein the skin ailment comprises lesions.

53. The formulation of claim 48, wherein the skin ailment comprises eczema.

54. The formulation of claim 48, wherein the skin ailment comprises atopic dermatitis.

55. The formulation of claim 48, wherein the skin ailment comprises hyperplasia of keratinocytes.

56. The formulation of claim 48, wherein the skin ailment comprises scaly plaques.

57. The formulation of claim 48, wherein the skin ailment comprises plaque psoriasis.

58. The formulation of claim 48, wherein the skin ailment comprises guttate psoriasis.

59. The formulation of claim 48, wherein the skin ailment comprises pustular psoriasis.

60. The formulation of claim 48, wherein the skin ailment comprises discreet erthymatous papules.

61. The formulation of claim 48, wherein the skin ailment comprises plaques covered with silvery scales.

62. The formulation of claim 48, wherein the skin ailment comprises scaly itchy patches that bleed when the scales are removed.

63. The formulation of claim 48, wherein the skin ailment comprises epidermal hyperplasia.

64. The formulation of claim 48, wherein the skin ailment comprises impaired cell-mediated immunity resulting in increased infections of the skin.

65. The formulation of claim 48, wherein the skin ailment comprises involvement of inflammatory T-cells.

66. The formulation of claim 65, wherein the T-cells express cutaneous lymphocyte antigen.

67. The formulation of claim 48, wherein the skin ailment is chronic.

68. The formulation of claim 48, wherein the skin ailment is recurrent.

69. The formulation of claim 48, wherein the formulation is substantially non-toxic.

70. The formulation of claim 48, wherein the formulation is substantially free of bad odor.

71. The formulation of claim 48, wherein the formulation is substantially non-staining.

72. The formulation of claim 48, further comprising an effective amount of a steroid compound.

73. The formulation of claim 48, wherein the formulation is substantially non-irritant.

74. A method for the treatment of skin ailments, the method comprising:

providing a formulation, the formulation further comprising:

approximately in the range of 5 - 25% glucosamine by weight;

approximately in the range of 1 - 10% berberine by weight;

approximately in the range of 0.5 - 7.5% oleuropein by weight; and

approximately in the range of 47.5 - 93.5% emollient by weight, and

topically applying the formulation to the affected skin.

75. A method for the treatment of skin ailments, the method comprising:

providing a formulation, the formulation further comprising glucosamine and extract from at least one herb, wherein the at least one herb extract elicits at least one of the following biological effects: anti-inflammatory, antioxidant, antibacterial, antimicrobial, anti-pruritic, anti-platelet adhesion, vasodilation or keratolysis, and

topically applying the formulation to the affected skin.

76. A method for the treatment of skin ailments, the method comprising:

providing a formulation, the formulation further comprising glucosamine and at least one antioxidant anti-inflammatory in an emollient base; and

topically applying the formulation to the affected skin.

77. The method of claim 76, wherein the skin ailment comprises psoriasis.

78. The method of claim 76, wherein the skin ailment comprises dermatitis.

79. The method of claim 76, wherein the skin ailment comprises hyperproliferation of apoptosis-resistant keratinocytes.

80. The method of claim 76, wherein the skin ailment comprises inflammatory lesions.

81. The method of claim 76, wherein the skin ailment comprises eczema.

82. The method of claim 76, wherein the skin ailment comprises atopic dermatitis.

83. The method of claim 76, wherein the skin ailment comprises hyperplasia of keratinocytes.

84. The method of claim 76, wherein the skin ailment comprises scaly plaques.

85. The method of claim 76, wherein the skin ailment comprises plaque psoriasis.

86. The method of claim 76, wherein the skin ailment comprises guttate psoriasis.

87. The method of claim 76, wherein the skin ailment comprises pustular psoriasis.

88. The method of claim 76, wherein the skin ailment comprises discreet erthymatous papules.

89. The method of claim 76, wherein the skin ailment comprises plaques covered with silvery scales.

90. The method of claim 76, wherein the skin ailment comprises scaly itchy patches that bleed when the scales are removed.

91. The method of claim 76, wherein the skin ailment comprises epidermal hyperplasia.

92. The method of claim 76, wherein the skin ailment comprises impaired cell-mediated immunity resulting in increased infections of the skin.

93. The method of claim 76, wherein the skin ailment comprises involvement of inflammatory T-cells.

94. The method of claim 93, wherein the T-cells express cutaneous lymphocyte antigen.

95. The method of claim 76, wherein the skin ailment is chronic.

96. The method of claim 76, wherein the skin ailment is recurrent.

97. The method of claim 76, wherein the formulation is substantially non-toxic.

98. The method of claim 76, wherein the formulation is substantially free of bad odor.

99. The method of claim 76, wherein the formulation is substantially non-staining.

100. The method of claim 76, wherein the formulation further comprises an effective amount of a steroid compound.

101. The method of claim 76, wherein the formulation is substantially non-irritant.